Viking Therapeutics falls 40% on drug data
Shares Viking Therapeutics The company dived on Tuesday after release Middle Stage Trial Data On the obesity pill that disappoints investors.
The stock price of the biotechnology firm fell to $ 23.80 on Tuesday morning, and at the closing of Monday to $ 43% from $ 43%. Viking’s market value is now about $ 2.69 billion, which is now more than $ 4 billion on Monday.
The results may be a blow to Viking, once seen as a hot M&A target, once trying to join the exploding market for obesity and diabetes drugs. Can strengthen Hand Lilly And Novo NordiskDomination in space develops pills for weight loss that can enter the markets before the tablet formulation of Viking’s drug, while VK2735.
Mizuho Health Services Strategist Jared Holz, on Tuesday, said, “Probably hoping for the hopes of the blinds. [Viking] To be a major time player in the oral obesity market in the middle and medium term. “
A more suitable obesity pill development race, Pfizer He had to scrape the previous contestants and reveal new ones.
Viking’s pill once a day helped patients lose 12.2% of their weight in about three months. The company also said that weight loss is not plateau, which means that patients may lose even more in a long -term study.
It is difficult to directly compare the second stage trial data of the pill, including the treatments developed by Eli Lilly and Novo Nordisk, with the results of oral drugs throughout the development.
Holz, Viking’s pills on the pill of Lilly’s oral medicine “almost all metrics” results “results lower”, he added. The highest dose of Eli Lilly’s daily pill helped patients to lose 12.4% of their body weight or 11.2% in the third stage at 72 weeks.
Holz drew attention to the high rate of patients with a high rate of 28%, which stopped Viking’s medication for any reason for any reason. Meanwhile, about a quarter of a quarter for any reason for any reason, Eli Lilly’s pill left Orborglpron.
This is a much longer experiment and therefore [Lilly] Head looks much better for Head, Hol Holz said.
Viking said that the most common causes of patients to stop treatment were gastrointestinal side effects, the majority of whom were moderately moderately and observed in the treatment. However, approximately 58% of the patients on the pill experienced nausea and 26% of them experienced vomiting compared to 48% and 10%, respectively.
During a shorter trial period, these side effect rates seem worse in the oral version of Wegovy, in the experiments on Eli Lilly’s pill, and the weight loss of Novo Nordisk.
The treatment of Viking works by imitating two naturally produced intestinal hormones called GLP-1 and GIP.
GLP-1 helps to reduce food intake and appetite. The envy, which suppresses appetite, can also improve the way the body breaks sugar and fats.
Eli Lilly’s pill and Novo Nordisk’s Oral version of Wegovy aims to GLP-1, but the latter has diet restrictions.
